C
CiVi Biopharma
The development of treatments for vascular diseases
About CiVi Biopharma
CiVi Biopharma Holding Corp. operates as a clinical-stage biotechnology firm, concentrating on the research and development of novel therapies for cardiovascular, metabolic, and orphan diseases. The company was established in 2017 by Chief Scientific Officer Henrik Ørum and is led by Chief Executive Officer Shal Jacobovitz. Dr. Ørum has over 25 years of experience in the biotechnology sector, having co-founded several successful companies, including Santaris Pharma A/S, which was acquired by Roche in 2014, where he then served as Global Head of RNA Therapeutics before founding CiVi Biopharma. Mr. Jacobovitz brings extensive leadership experience from his previous roles as CEO of the American College of Cardiology and President of Actelion Pharmaceuticals U.S.
The company's business model is centered on identifying and advancing a pipeline of drug candidates to address significant unmet medical needs. CiVi Biopharma in-licenses promising drug technologies and progresses them through preclinical and clinical development stages. Its funding model is based on venture capital, having raised approximately $120-165 million from investors including Boxer Capital, Roche Venture Fund, Tang Capital, and RA Capital. The company's primary focus is on developing its assets to a stage where they can be commercialized, potentially through partnerships or out-licensing agreements with larger pharmaceutical companies.
CiVi Biopharma's pipeline includes several assets at various stages of development. A key product is CiVi 008, a third-generation oral PCSK9 antisense molecule designed for the treatment of hypercholesterolemia and the prevention of atherosclerotic cardiovascular disease. Another significant program, developed through its subsidiary Eicos Sciences, Inc., is CiVi 030, an intravenous formulation of iloprost for treating severe frostbite. The company leverages proprietary technologies, such as the LNA (Locked Nucleic Acid) drug technology licensed from Roche and a GI drug absorption enhancement platform called COPE, to enable the development of its oligonucleotide-based therapies.
Source: Dealroom company dataNews
Open roles
CiVi Biopharma in the Chevy Chase Village ecosystem
The CiVi Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Tavistock Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CiVi Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CiVi Biopharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

